Document Detail

Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism.
MedLine Citation:
PMID:  11403366     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine whether an angiotensin II receptor antagonist decreases blood pressure in patients with hyperaldosteronism and hypertension who are taking other antihypertensive agents. DESIGN: A double-blind randomized placebo-controlled crossover study. PATIENTS AND METHODS: Blood pressure and hormonal responses to 2-week courses of placebo/irbesartan (150 mg/day given by mouth at 08.05 h) were assessed in 10 patients with hyperaldosteronism. Clinic blood pressure was measured by sphygmomanometer, and plasma concentrations of aldosterone, cortisol, angiotensin II, electrolytes and renin activity (PRA) were determined weekly. Automated 24 h ambulatory blood pressure recordings were made at the end of the active and placebo phases. RESULTS: Irbesartan caused a post-dose decrease in ambulatory blood pressure (systolic, P = 0.02; diastolic, P = 0.05) in the period from 10.00 h to 20.00 h. Clinic blood pressure, measured at trough, was not significantly decreased. Plasma aldosterone decreased (P < 0.03) and PRA increased (P < 0.04) in the first week of active treatment with irbesartan, but differences between the placebo and active-treatment groups were not significant in the second week. There were no significant changes in plasma concentrations of angiotensin II, cortisol or potassium in either week. In the second week of irbesartan treatment, there were associations between change in plasma aldosterone and maximal change in ambulatory blood pressure (systolic and diastolic). CONCLUSION: Irbesartan has a role in combination antihypertensive treatment of patients with hyperaldosteronism.
G S Stokes; J C Monaghan; M Ryan; M Woodward
Related Documents :
16957426 - Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal ...
979066 - The effect of saralasin (1sar-8-ala-angiotensin ii) on blood pressure in patients with ...
6625516 - Surgical treatment of primary aldosteronism.
18347776 - Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effec...
3176716 - A delayed drowning death with histological findings of shock.
11840226 - Weak effect of hypertension and other classic risk factors in the elderly who have alre...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of hypertension     Volume:  19     ISSN:  0263-6352     ISO Abbreviation:  J. Hypertens.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-06-13     Completed Date:  2001-12-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  1161-5     Citation Subset:  IM    
Department of Cardiology, Royal North Shore Hospital, St Leonards, NSW, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone / blood
Antihypertensive Agents / therapeutic use
Biphenyl Compounds / therapeutic use*
Blood Pressure / drug effects
Cross-Over Studies
Double-Blind Method
Hyperaldosteronism / blood,  drug therapy*,  physiopathology
Middle Aged
Receptors, Angiotensin / antagonists & inhibitors*
Renin / blood
Tetrazoles / therapeutic use*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Receptors, Angiotensin; 0/Tetrazoles; 138402-11-6/irbesartan; 52-39-1/Aldosterone; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of individual risk factors on the incidence of cardiovascular events in the treated hyperten...
Next Document:  Regression of left ventricular hypertrophy in human hypertension with irbesartan.